Patent ID: 11858905
Assignee: RK PHARMTECH (BEIJING) LTD.
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 19:
20. A method of treating a disease in a subject, comprising:
administering a composition to a subject suffering from the disease, the composition including a compound represented by formula (I-a):, , an enantiomer thereof, a diastereomer thereof, a racemate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, in a pharmaceutically effective amount, wherein
R1 and R2 are independently selected from H, a —CH2— group, and an alkyl group;
R1 and R2 are unconnected or connected via a single bond;
W is CO or SO2;
R3 is an alkyl group, a fluoroalkyl group, a cycloalkyl group, an alkoxy group, an aryl group, a heteroaryl group, or a heterocyclic group, and R3 is optionally substituted by one or more groups selected from halogen, a hydroxyl group, an alkyl group, a fluoroalkyl group, a cycloalkyl group, an aryl group, a heterocyclic group, and an alkoxy group;
X1 is a CH group or N;
X2 is O, S, or N—R4, wherein R4 is selected from H, an alkyl group, an aryl group, and a heterocyclic group;
X3 is H, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, or a heterocyclic group, and X3 is optionally substituted by one or more groups selected from halogen, a hydroxyl group, an alkyl group, a fluoroalkyl group, a cycloalkyl group, and an alkoxy group;
Z1 is a CH group, C—R5, or N;
Z2 is a CH group, C—R6, or N;
Z3 is a CH group, C—R7, or N; and
Z4 is a CH group, C—R8, or N, wherein
R5—R8 are independently selected from H, halogen, a hydroxyl group, an alkyl group, a fluoroalkyl group, —CN, a cycloalkyl group, an alkoxy group, an aryl group, a heteroaryl group, and a heterocyclic group, and

each of R5-R8 is optionally substituted by one or more groups selected from halogen, a hydroxyl group, an alkyl group, a fluoroalkyl group, a cycloalkyl group, a heterocyclic group, a cycloalkyl group, an aryl group, and an alkoxy group,
wherein the disease is a severe acute respiratory syndrome (SARS), a coronavirus disease 19 (COVID-19), long-term effects of coronavirus (long COVID), post-acute sequelae of COVID-19 (PASC), respiratory syncytial virus (RSV) infection, ebola virus infection, middle east respiratory syndrome (MERS), herpes simplex virus infection, acute respiratory distress syndrome (ARDS), ARDS-induced multiple organ failures, acute kidney injury (AKI), liver injury, liver fibrosis, cancer, osteoporosis, inflammation, atherosclerosis, a renal disease, a bone disease, or diabetes.